iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
-
- Michael Hallek
- Klinik I für Innere Medizin, Universität zu Köln, Cologne, Germany;
-
- Bruce D. Cheson
- Lombardi Cancer Center, Georgetown University Hospital, Washington, DC;
-
- Daniel Catovsky
- Institute of Cancer Research, London, United Kingdom;
-
- Federico Caligaris-Cappio
- Department of Oncohematology, Universita Vita-Salute San Raffaele, Milan, Italy;
-
- Guillermo Dighiero
- Institut Pasteur, Montevideo, Uruguay;
-
- Hartmut Döhner
- Department III of Internal Medicine, University of Ulm, Ulm, Germany;
-
- Peter Hillmen
- St James’s Institute of Oncology, Leeds, United Kingdom;
-
- Michael Keating
- Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX;
-
- Emili Montserrat
- Hospital Clinic, University of Barcelona, Barcelona, Spain;
-
- Nicholas Chiorazzi
- Feinstein Institute for Medical Research, Manhasset, NY;
-
- Stephan Stilgenbauer
- Department III of Internal Medicine, University of Ulm, Ulm, Germany;
-
- Kanti R. Rai
- Feinstein Institute for Medical Research, Manhasset, NY;
-
- John C. Byrd
- Division of Hematology, The Ohio State University, Columbus, OH;
-
- Barbara Eichhorst
- Klinik I für Innere Medizin, Universität zu Köln, Cologne, Germany;
-
- Susan O’Brien
- Division of Hematology/Oncology, School of Medicine, University of California, Irvine, CA;
-
- Tadeusz Robak
- Department of Hematology, Medical University of Lodz, Lodz, Poland;
-
- John F. Seymour
- Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; and
-
- Thomas J. Kipps
- Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA
Description
<jats:title>Abstract</jats:title> <jats:p>The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion–based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.</jats:p>
Journal
-
- Blood
-
Blood 131 (25), 2745-2760, 2018-06-21
American Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1363388845788197120
-
- ISSN
- 15280020
- 00064971
-
- Data Source
-
- Crossref
